Cargando…
Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19”
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585627/ https://www.ncbi.nlm.nih.gov/pubmed/33115645 http://dx.doi.org/10.1016/j.clim.2020.108617 |
| _version_ | 1783599831126638592 |
|---|---|
| author | Mastellos, Dimitrios C. Lambris, John D. |
| author_facet | Mastellos, Dimitrios C. Lambris, John D. |
| author_sort | Mastellos, Dimitrios C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7585627 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75856272020-10-26 Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19” Mastellos, Dimitrios C. Lambris, John D. Clin Immunol Letter to the Editor Published by Elsevier Inc. 2021-01 2020-10-25 /pmc/articles/PMC7585627/ /pubmed/33115645 http://dx.doi.org/10.1016/j.clim.2020.108617 Text en © 2020 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Mastellos, Dimitrios C. Lambris, John D. Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19” |
| title | Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19” |
| title_full | Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19” |
| title_fullStr | Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19” |
| title_full_unstemmed | Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19” |
| title_short | Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19” |
| title_sort | response to “comment on mastellos and colleagues and efficacy of complement-targeting drugs in covid-19” |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585627/ https://www.ncbi.nlm.nih.gov/pubmed/33115645 http://dx.doi.org/10.1016/j.clim.2020.108617 |
| work_keys_str_mv | AT mastellosdimitriosc responsetocommentonmastellosandcolleaguesandefficacyofcomplementtargetingdrugsincovid19 AT lambrisjohnd responsetocommentonmastellosandcolleaguesandefficacyofcomplementtargetingdrugsincovid19 |